Thermo Fisher Scientific announced the global launch of two new platforms that target the rapidly expanding cell‑therapy and biologics markets: the Gibco CTS Compleo Fill and Finish System and the Gibco CHOvantage GS Cell Line Development Kit.
The CTS system is an automated, functionally closed solution that streamlines formulation and filling for cell‑therapy manufacturing. By addressing the variability in patient‑derived cell counts, concentrations and viability that is common in cell‑therapy workflows, the system reduces manufacturing risk and improves consistency across production runs.
The CHOvantage GS kit delivers high‑productivity CHO cell lines, achieving protein titers of at least 7 g/L in fed‑batch cultures and enabling stable clone selection within 14 weeks. The platform also offers royalty‑free, clinical‑stage licensing options, which can shorten development timelines and lower costs for biopharma customers.
Thermo Fisher’s Q4 2025 results provide a strong backdrop for these launches. Revenue rose 7% to $12.21 billion and adjusted EPS reached $6.57, beating analyst estimates of $6.45. Full‑year 2025 revenue totaled $44.56 billion, up 4% from 2024, while the adjusted operating margin for the quarter was 23.6% versus 23.9% a year earlier. These figures demonstrate the company’s robust execution and the momentum that supports new product introductions.
The cell‑therapy market is projected to grow at a 16.5% CAGR through 2030, reaching $5.6 billion in 2025, while the global biologics market is expected to expand to $487 billion in 2025 and grow at 9.8% through 2035. Thermo Fisher has invested $3 billion in manufacturing capabilities for cell and gene therapies since 2019, positioning it to capture a share of these high‑growth segments.
CEO Marc N. Casper highlighted the company’s performance, noting, "Thanks to our exceptional team, we delivered a strong finish to 2025, reflecting outstanding execution and the continued strength of our proven growth strategy." This statement underscores the confidence with which Thermo Fisher is pursuing these new platforms.
These launches reinforce Thermo Fisher’s leadership in life‑sciences solutions and align with its strategy to provide integrated, automated tools that accelerate development and manufacturing in the cell‑therapy and biologics markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.